[The role of fetal echocardiography during maternal pharmacological treatment].
OBJECTIVE
Fetal tricuspid valve regurgitation (TR) has been described in the literature in association with congenital heart defects, congestive heart failure, fetal cardiac arrhythmias and ductal occlusion. TR is very often present during echocardiographic examinations without structural anomalies of fetal heart and without extracardiac malformations (ECM).


METHODS
The aim of this study was an analysis of fetal TR in cases without ECM and with normal heart anatomy (NHA) in 43/100 (43%) fetuses with maternal treatment.


RESULTS
In the study group the most common finding of TR with NHA was exposure to betamimetic. Fetal echocardiography was helpful in these cases to confirm the safety and fetal well-being during maternal pharmacological treatment due to premature labour.
D000328:Adult; D004452:Echocardiography; D005260:Female; D006801:Humans; D007752:Obstetric Labor, Premature / Q000188:drug therapy* / Q000517:prevention & control; D011044:Poland; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D012189:Retrospective Studies; D015149:Tocolytic Agents / Q000009:adverse effects*; D014262:Tricuspid Valve Insufficiency / Q000000981:diagnostic imaging*; D016216:Ultrasonography, Prenatal
D015149:Tocolytic Agents
Znaczenie badania echokardiograficznego w przebiegu farmakoterapii płodu lub ciezarnej.